Get started
Author

Andrea E. Formella

Observed names: A. Formella, A.E. Formella, Andrea E Formella, Andrea Formella, Formella, Andrea, Formella, Andrea E.
ORCID: 0000-0003-2737-7898
Observed ORCID: 0000-0003-2737-7898
OpenAlex ID: A5057886606
Pseudobulbar Affect: Burden of Illness in the USA
2012 · Jennifer Colamonico, Andrea Formella, et al. · Advances in Therapy · 71
PDF
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
2014 · Gary L. Pattee, James P. Wymer, et al. · Current Medical Research and Opinion · 38
PDF
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
2016 · Flora M. Hammond, David N. Alexander, et al. · BMC Neurology · 36
PDF
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
2022 · Robert A. Hauser, Judy Lytle, et al. · npj Parkinson s Disease · 31
PDF
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
2021 · Robert A. Hauser, Ryan R. Walsh, et al. · Frontiers in Neurology · 24
PDF
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study
2025 · Stuart H Isaacson, Alberto J Espay, et al. · Journal of Parkinson s Disease · 22
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM‐II Open Label Study
2018 · Flora M. Hammond, William Sauve, et al. · PM&R · 22
Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
2021 · Robert A. Hauser, Shyamal H. Mehta, et al. · Neurology and Therapy · 14
PDF
Extended-release amantadine for OFF-related dystonia in Parkinson's disease
2024 · Alberto J. Espay, Jill L. Ostrem, et al. · Parkinsonism & Related Disorders · 10
PDF
Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors
2025 · Brittney Yegla, Jonathan Rubin, et al. · Journal of Neural Transmission · 7
PDF
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
2024 · Ann Childress, Andrew J. Cutler, et al. · CNS Drugs · 7
PDF
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
2022 · Rajesh Pahwa, Susan Fox, et al. · Frontiers in Neurology · 7
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial
2018 · Richard D. Zorowitz, David N. Alexander, et al. · PM&R · 7
PDF
Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg ( GAERS ) model of genetic generalized epilepsy with absence seizures
2024 · Pablo M. Casillas‐Espinosa, Jennie Garcia‐Olivares, et al. · Epilepsia Open · 5
Gocovri Reduces Disruptive Motor Episodes and Improves Function in Parkinson’s Disease Patients With OFF Episodes and Dyskinesia: Analysis of Phase 3 Trial Data (1882)
2020 · Robert Hauser, Dustin Chernick, et al. · Neurology · 4
Use of Real-World Data to Evaluate the Importance of Antiemetic Pretreatment for Apomorphine hydrochloride [APO, Apokyn®] subcutaneous Injection Initiation and Maintenance in People with Parkinson Disease (P13-11.016)
2023 · Cindy Happel, Mindy Grall, et al. · Neurology · 3
Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy
2021 · Robert A. Hauser, Santosh Goud, et al. · Clinical Parkinsonism & Related Disorders · 3
PDF
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
2016 · Flora M. Hammond, David N. Alexander, et al. · BMC Neurology · 3
PDF
A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138
2026 · Steven D. Targum, Gerard Sanacora, et al. · Journal of Psychiatric Research · 2
Qelbree (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with ADHD
2024 · Ann Childress, Andrew Cutler, et al. · CNS Spectrums · 2
PDF
Safety and Tolerability of Dextromethorphan/Quinidine in Older Patients
2017 · Stephen D'Amico, David N. Alexander, et al. · American Journal of Geriatric Psychiatry · 2
An Open-Label Study to Assess Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect (PBA) in Dementia, Stroke and Traumatic Brain Injury: PRISM II Combined Cohort Results for Patients Aged ≥65 Years
2016 · Flora Hammond, David N. Alexander, et al. · American Journal of Geriatric Psychiatry · 2
Abstract 107: Dextromethorphan/Quinidine for Treatment of Pseudobulbar Affect Secondary to Stroke: Results from the PRISM-II Study
2016 · Richard Zorowitz, David Alexander, et al. · Stroke · 2
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Stroke: PRISM-II
2015 · Richard D. Zorowitz, David N. Alexander, et al. · Archives of Physical Medicine and Rehabilitation · 2
Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-term Data from the Ongoing InfusON Extension Study (P11-5.027)
2025 · Peter LeWitt, Stuart Isaacson, et al. · Neurology · 1
Works count: 48
Citation count: 330
H-index: 9
I10-index: 9
Year
Topic
Type